The Unprecedented Rise of ARCA biopharma Inc. (NASDAQ:ABIO)

The Unprecedented Rise of ARCA biopharma Inc. (NASDAQ:ABIO)


The ARCA biopharma Inc. (ABIO) shares are trading at higher $7.10. while the current analyst price target stands at $7.00.

To add more color to this target, the company’s high over the last year is $22.00 and the low is $2.21. Over the last 52 weeks, ABIO is down -67.73% while the S&P 500 is down -0.36%. The catalyst for this interesting swing was the company’s recent earnings report.

A Notable Earnings Report

In the last quarter, ABIO reported a profit of $4000.0. ARCA biopharma Inc. also saw revenues increase to $1.34 million. In addition, ABIO has free cash flow of -$1.69 million as of 03-2020. The company’s EBITDA came in at -$1.31 million which compares well with its peers.

ABIO Return on Equity (ROE) is -64.40%, and its Return on Assets is -56.60%. All told, it is clear that, ABIO needs to be on your watchlist.

Find out when ABIO reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. ABIO has a short ratio of 0.01 and outstanding shares of 1.59M.

Company Outlook

ABIO has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 1.38 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -3.49. ARCA biopharma Inc. ABIO also noted assets of $7.46 million at the end of the last quarter. Investors should also keep an eye on sector updates as ABIO has historically followed its peers on positive news.

All told, ARCA biopharma Inc. ABIO has strung together solid data and demonstrated underlying fundamentals. At its current valuation, ABIO represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.

ARCA biopharma Inc. ABIO is now commanding a market cap of 30.53M and a float of 1.18M. ABIO is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of ABIO stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in ABIO, either long or short, and we have not been compensated for this article.